Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBS1BS2
The NM_001177306.2(PAM):āc.1688A>Gā(p.Asp563Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0422 in 1,599,210 control chromosomes in the GnomAD database, including 1,705 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
PAM (HGNC:8596): (peptidylglycine alpha-amidating monooxygenase) This gene encodes a multifunctional protein. The encoded preproprotein is proteolytically processed to generate the mature enzyme. This enzyme includes two domains with distinct catalytic activities, a peptidylglycine alpha-hydroxylating monooxygenase (PHM) domain and a peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL) domain. These catalytic domains work sequentially to catalyze the conversion of neuroendocrine peptides to active alpha-amidated products. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016]
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.008397847).
BS1
Variant frequency is greater than expected in population nfe. GnomAd4 allele frequency = 0.0311 (4731/152258) while in subpopulation NFE AF = 0.0496 (3370/67996). AF 95% confidence interval is 0.0482. There are 108 homozygotes in GnomAd4. There are 2277 alleles in the male GnomAd4 subpopulation. Median coverage is 32. This position FAILED quality control check.